Compositions including antibiotics and methods for using same

Abstract

Compositions including a quinolone component, such as ofloxacin, having fungistatic activity in the compositions, present in an amount effective as an antibiotic when the composition is placed in a mammalian eye, a NSAID component present in an amount to reduce inflammation or pain when the composition is placed in the eye, and a carrier component in an amount effective to act as a carrier for the quinolone component and NSAID component are provided. Methods of using the present compositions, for example, to resolve microbial infections and/or to reduce inflammation and/or pain in a mammalian eye are included within the scope of the present invention. Methods for treating corneal injuries are also included. In addition, methods for treating ocular infections, for example, corneal infections, are included.

What is claimed is:  
     
         1 . A composition comprising: 
 a quinolone component in an amount effective as an antibiotic when the composition is placed in a mammalian eye, the quinolone component in the compositions having fungistatic activity;    a NSAID component in an amount effective to reduce inflammation or pain when the composition is placed in a mammalian eye; and    a carrier component in an amount effective to act as a carrier for the quinolone component and the NSAID component in the composition, the carrier component being ophthalmically acceptable.    
     
     
         2 . The composition of  claim 1  wherein the NSAID component is a ketorolac component.  
     
     
         3 . The composition of  claim 1  or  2  wherein the quinolone component is an ofloxacin component.  
     
     
         4 . The composition of any of claims  1 - 3  wherein said composition contains substantially no addition components which are active as a preservative.  
     
     
         5 . A method for treating a mammalian eye comprising: 
 administering to the mammalian eye a therapeutically effective amount of the composition of any of claims  1 - 4 , thereby providing an effective antibiotic in the mammalian eye and reducing inflammation or pain in the mammalian eye.    
     
     
         6 . A method for reducing pain in a mammalian eye comprising: 
 administering to a mammalian eye in need of pain reduction a therapeutically effective amount of the composition of claims  1 - 4  in an amount effective to provide a reduction in pain to the mammalian eye.    
     
     
         7 . A method for treating a corneal injury comprising: 
 administering to a mammalian eye having a corneal injury a therapeutically effective amount of a composition comprising a quinolone component in an amount effective as an antibiotic in the mammalian eye and a NSAID component in an amount effective, in combination with the quinolone component, to provide a reduction in paid caused by the corneal injury.    
     
     
         8 . The method of  claim 9  wherein the quinolone component is an ofloxacin component, the NSAID component is a ketorolac component, and the corneal injury is a corneal ulcer.  
     
     
         9 . A method for treating an ocular infection comprising: 
 administering to a mammalian eye having an infection caused by one or more pathogens a therapeutically effective amount of a composition comprising a quinolone component in an amount effective as an antibiotic in the mammalian eye and a NSAID component in an amount effective to reduce the time needed to eliminate the infection relative to identically administering a similar composition without the NSAID component.    
     
     
         10 . The method of  claim 9  wherein the administering step is effective to inhibit colonization of the one or more pathogens in the mammalian eye.  
     
     
         11 . The method of  claim 9  or  10  wherein the mammalian eye includes a surface and the administering step is effective to at least inhibit the one or more pathogens from adhering to the surface.  
     
     
         12 . The method of any of claims  9 - 11  wherein the ocular infection is a corneal infection.  
     
     
         13 . The method of any of claims  9 - 12  wherein the administering step is effective to inhibit colonization of the one or more pathogens in the mammalian eye.  
     
     
         14 . The method of any of claims  9 - 13  wherein the administering step is effective to at least inhibit the one or more pathogens from adhering to a cornea of the eye.  
     
     
         15 . The method of any of claims  9 - 14  herein the quinolone component is a halogenated quinolone component.  
     
     
         16 . The method of  claim 15  wherein the quinolone component is a fluorinated quinolone component.  
     
     
         17 . The method of  claim 16  wherein the quinolone component is an ofloxacin component.  
     
     
         18 . The method of any of claims  9 - 17  wherein said composition contains substantially no additional components which are active as preservatives.  
     
     
         19 . The method of any of claims  9 - 18  wherein the NSAID component is a carboxyl group-containing NSAID component.  
     
     
         20 . The method of  claim 19  wherein the NSAID component is a ketorolac component.  
     
     
         21 . A method for treating an ocular infection comprising: 
 administering to a mammalian including at least one surface; and    an eye having an infection caused by one or more pathogens a therapeutically effective amount of a composition comprising a quinolone component in an amount effective as an antibiotic in the mammalian eye and an NSAID component in an amount effective to at least inhibit the one or more pathogens from adhering to the surface.    
     
     
         22 . A method for treating an ocular infection comprising: 
 administering to a mammalian eye having an infection caused by one or more pathogens a therapeutically effective amount of a composition comprising a quinolone component in an amount effective as an antibiotic in the mammalian eye and a NSAID component in an amount effective to inhibit colonization of the one or more pathogens in the mammalian eye.    
     
     
         23 . The method of either of claims  21  or  22  wherein the ocular infection is a corneal infection.  
     
     
         24 . The method of any of claims  21 - 23  wherein the quinolone component is a halogenated quinolone component.  
     
     
         25 . The method of any of claims  21 - 24  wherein the quinolone component is a fluorinated quinolone component.  
     
     
         26 . The method of any of claims  21 - 25  wherein the quinolone component is an ofloxacin component.  
     
     
         27 . The method of  claim 26  wherein the quinolone component is an ofloxacin component  
     
     
         28 . The method of any of claims  21 - 27  wherein the NSAID component is a carboxyl group-containing NSAID component.  
     
     
         29 . The method of any of claims  21 - 28  wherein the NSAID component is a ketorolac component.  
     
     
         30 . A composition comprising: 
 a quinolone component in an amount effective as an antibiotic when the composition is placed in a mammalian eye, the quinolone component in the compositions having fungistatic activity;    a carrier component in an amount effective to act as a carrier for the quinolone component and the NSAID component in the composition, the carrier component being ophthalmically acceptable;    wherein said composition contains substantially no additional components effective to act as a preservative.    
     
     
         31 . The composition of claims  30  wherein said quinolone component is a fluorinated quinolone component.  
     
     
         32 . The composition of  claim 31  wherein said quinolone component is olfloxacin.